- Aegis is out with bullish commentary on both Catalyst Pharmaceuticals (CPRX +5.4%) and CytRx (CYTR +7.6%), both of which are moving higher today on news.
- "Time to completion of enrollment of the Firdapse Phase 3 trial has been extended into the first quarter of this year, but we remain confident that the enrollment pace is progressing adequately," analyst Ram Selvaraju says, maintaining a Buy rating and a $6 target on CPRX.
- As for CYTR, Selvaraju lifts his target to $9 from $8 after discussing results from additional statistical analyses of a Phase 2b aldoxorubicin study.
Aegis out positive on Catalyst, CytRx after news
Jan 8 2014, 13:42 ET